Australia's EchoIQ climbs to 7-1/2-year high on new CEO appointment, FDA clearance
09/10/2024 05:22
** Shares of EchoIQ EIQ.AX rise as much as 25% to A$0.300,
their highest levels since May 25, 2017
** Stock posts its biggest intraday pct gain since
late-March
** The health tech firm appoints U.S.-based Dustin Haines as
new CEO
** Co said on Tuesday it received clearance for its
decision-support tool for heart valve disease EchoSolv AS from
the U.S. Food and Drug Administration
** Says the approval will allow the product to be marketed
and sold in the U.S.
** Over 36.9 mln shares change hands, 11.4x the 30-day avg
** Co stock up 67.7% YTD, including current session's moves
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Recent news on EchoIQ
See all newsAustralia's EchoIQ gains most in nearly 3 months after FDA update
Brief: EchoIQ Says FDA Raises No Concerns About Echosolv HF Technology Or Core Functionality
Australia's EchoIQ heads for worst week in seven years after US FDA setback
Australia's Echo IQ logs worst day in seven years after FDA setback
Brief: EchoIQ Requests Trading Halt